



## Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Feb 11, 2025

### **February 11-12, 2025, Snowbird, Utah**

IRVINE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend BTIG's MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah. Oncocyte will host one-on-one meetings with interested investors.

Investors attending the conference wishing to schedule a meeting are encouraged to contact BTIG to schedule.

**Event:** BTIG's MedTech, Digital Health, Life Science & Diagnostic Tools Conference 2025

**Dates:** February 11-12, 2025

**Location:** Snowbird, Utah, USA

### **About Oncocyte**

Oncocyte is a leading diagnostics technology company. The company's tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit <https://oncocyte.com/>. For more information about our products, please visit the following web pages:

**VitaGraft Kidney™** - <https://oncocyte.com/vitagraft-kidney/> **VitaGraft Liver™** -

<https://oncocyte.com/vitagraft-liver/>

**GraftAssure™** - <https://oncocyte.com/graftassure/>

**DetermaIO™** - <https://oncocyte.com/determa-io/> **DetermaCNI™** -

<https://oncocyte.com/determa-cni/>

**VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.**

### **CONTACT:**

Jeff Ramson

PCG Advisory

(646) 863-6893

[jramson@pcgadvisory.com](mailto:jramson@pcgadvisory.com)



Source: OncoCyte Corporation

